Bremelanotide

Also known as: Vyleesi, PT-141

Status

FDA-approved. Approved since 2019 as Vyleesi for premenopausal hypoactive sexual desire disorder. The 'PT-141' research-chemical market is a different product from the approved auto-injector.

What it is

A melanocortin agonist — a modified peptide acting on melanocortin receptors in the brain rather than on blood vessels, which is what separates its mechanism from the PDE5 pills.

Source

FDA prescribing information (Vyleesi)

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.